Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

NCT ID: NCT05371275

Last Updated: 2022-11-07

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-21
• Study Completion Date: 2022-12-31

Brief Summary

This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.

Detailed Description

The study will include hospitalized, moderate COVID-19 cases that have a risk of respiratory failure.

The study will generally consist of:

• A short screening phase (1 day) before enrollment and thus treatment decision.
• A 21 day treatment phase with one "cycle" of palbociclib
• An up to day 90 Safety Follow-Up Phase

The first three patients will be enrolled and treated one by one; the independent safety data review committee (ISRC) will review each patient after D21 before enrollment of the subsequent patient is permitted.

Conditions

COVID-19

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Palbociclib

125 mg of palbociclib once daily for 21 consecutive days

Group Type: EXPERIMENTAL

Palbociclib

Intervention Type: DRUG

125 mg of palbociclib once daily for 21 consecutive days

Interventions

Palbociclib

125 mg of palbociclib once daily for 21 consecutive days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. age >= 18 years

2. positive PCR COVID-19 test (max. 72h old)

3. known vaccination status

4. ANC >= 1,000/mm3 and platelets >= 50,000/mm3

5. willingness to participate (written informed consent)

6. established risk factors for a severe course of COVID-19-disease, for example: adipositas, cardiovascular disease including arterial hypertension, advanced age > 60, chronic lung disease including asthma, diabetis type I or II, chronic kidney disease, chronic liver disease

7. Oxygen supply: ≤ 2 liters/minute

8. Women of childbearing potential (WOCBP): must have a negative pregnancy test (ß- HCG urine or serum test) a. WOCBP is considered as i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile.

b. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

c. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

9. Use of highly effective contraception method

1. All potentially fertile participants, or their male partners, must use an adequate, medically approved method of contraception or agree to abstinence during and at least 3 weeks (females) and 14 weeks (males) after treatment with Palbociclib.

2. For females, highly effective birth control should be used, i.e., combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, or intrauterine hormone-releasing system, bilateral tubal occlusion and vasectomized partner. As there is no information available on the interaction of palbociclib with oral contraceptives, a double-barrier contraception is necessary in this case.

3. Males must agree to use a condom for at least 14 weeks after the treatment phase.

Exclusion Criteria

1. age < 18 year

2. ECOG >= 3

3. ANC < 1,000/mm3 and platelets < 50,000/mm3

4. intensive care patient

5. treatment with any other CDK4/6 Inhibitor

6. pregnant or breast-feeding women

7. patients receiving immunosuppressants for other diseases (e.g. rheumatoid arthritis)

8. known malignancy in the past 5 years other than basal cell carcinoma

9. baseline O2-Saturation < 92%

10. participation in any other medical device or medicinal product study within the previous month

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

biotx.ai GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Reinwald, PD Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Brandenburg an der Havel

Locations

Universitätsklinikum Brandenburg an der Havel

Brandenburg, , Germany

Countries

Germany

Other Identifiers

2021-006770-24

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BXAI-001

Identifier Type: -

Identifier Source: org_study_id